Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.6M
21M shares
52-week range
$0.27 – $2.11
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
www.kairospharma.comNo one on the platform currently holds KAPA.
No tracked institution reports a position in KAPA as of their last filing.
No one on the platform has traded KAPA yet.
$KAPA How's all the quiet bag holders? Why the high volume w no movement or news?? Diluting? Either way, AQST hit, ready for much more. VELO hit, wow. MNTS is next. I recommend contacting ROSEN LAW if you were mislead by CEO and lost $. His is a PC of dog sht
View on StockTwits ↗$KAPA INSIDER OWNERSHIP?? CEO ONLY OWNS HIS SHARES THRU A TRUST FUND. DONU THINK HE ACTUALLY GIVES A SHT? CALL ROSEN LAW
View on StockTwits ↗$KAPA Those who listened!! $BCDA is next. Load the boat before it takes off.
View on StockTwits ↗$KAPA I think this has bottomed and should have plenty of room to go…great news with that Bayer partnership
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $0 | — | $-0.33 | $-0.33–$-0.33 | — | 1 |
| 2027 | $0 | — | $-0.51 | $-0.51–$-0.51 | — | 1 |
| 2028 | $0 | — | $-0.56 | $-0.73–$-0.38 | — | 2 |
| 2029 | $28M | — | $-0.37 | $-0.37–$-0.37 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $-0.09 | $-0.06 | +33.3% |
| 2026-05-13 | $-0.07 | $-0.08 | -14.3% |
| 2026-03-31 | $-0.02 | $-0.07 | -275.3% |
| 2025-11-14 | $-0.10 | $-0.07 | +30.0% |
| 2025-08-12 | $-0.06 | $-0.08 | -33.3% |
| 2025-04-15 | $-0.05 | $-0.08 | -60.0% |
| 2025-02-26 | $-0.06 | $-0.09 | -43.8% |
| 2024-11-14 | $-0.02 |
| $-0.10 |
| -400.0% |
| $67M |
| — |
| CLSDClearside Biomedical, Inc. | $0.41 | +0.00% | $2M | — |
| ENTOEntero Therapeutics, Inc. | $2.85 | -5.00% | $14M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.